Skip to main content

Table 2 Included HTA-reports related to orphan drugs case studies

From: Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports

Intervention (indication)

HTA organisation

Publication date

Consideration of manufacturers’ cost in relation to drug price?

Eculizumab (PNH)

PBAC

July 2008

No

PBAC

March 2009

No

CADTH

February 2010

No

PBAC

July 2010

No

ZIN

May 2016

Yes

ZIN

June 2017

Yes

Eculizumab (aHus)

PBAC

March 2013

No

CADTH

July 2013

No

PBAC

March 2014

No

PBAC

August 2014

No

NICE

January 2015

Yes

CADTH

May 2015

No

ZIN

November 2016

Yes

Lumacaftor/ivacaftor (CF)

PBAC

March 2016

No

ZIN

May 2016

Yes

NICE

July 2016

No

CADTH

October 2016

No

PBAC

November 2016

No

ZIN

December 2016

Yes

PBAC

July 2017

No

PBAC

July 2018

No

  1. HTA  health technology assessment, PBAC  Pharmaceutical Benefit scheme and medical services Advisory Committee, CADTH Canadian Agency for Drugs and Technologies in Health, ZIN Zorginstituut Nederland, NICE National Institute for Health and Care Excellence, PNH  paroxysmal nocturnal haemoglobinuria, aHus  atypical haemolytic uraemic syndrome, CF  cystic fibrosis